Journal Finder

Prostate Cancer is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies related to all aspects of prostate cancer.

Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management.Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, BPH and prostatitis.Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.The following is a non-exhaustive list of the general topics covered by Prostate Cancer and Prostatic Diseases: * Alternative therapies * Angiogenesis * Anti-sense oligonucleotides against growth factors * Brachytherapy * Conformal radiotherapy * Cryotherapy * Cyclotron fast neutron treatment * Enhancing the results of radical prostatectomy * Epidemiology of prostate cancer and prostatic diseases * Familial prostate cancer * Free to total PSA * Gene therapy for prostate cancer * Genetic basis for prostate cancer Hormone-related disease * How significant is PSA-detected disease? * Intermittent antiandrogen therapy * Mechanisms of tumour invasion in prostate cancer * Medical and surgical therapies for BPH * Medical therapy for BPH: the road ahead * Natural history of prostate cancer and prostatic diseases * Nutrition in prostate cancer and prostatic diseases * Photodynamic therapy * Prognostic markers * Prostate cancer and potency and impotence * Prostatic intra-epithelial neoplasia - an important precursor of cancer * Prostatitis: quo vadis? * Quality of life issues * Racial issues in prostate cancer * Recurrence after radical prostatectomy * Reproducibility (test-retest reliability) of investigations for prostatic diseases * Reverse transcriptase polymerase chain reaction to detect circulating mRNA for PSA * Role of differentiation therapy * Screening for prostate cancer * Staging of prostate cancer: beyond conventional imaging * The magic bullet - use of PSA promotor gene to target gene therapy * Utility of ultrasensitive PSA assays.

RSC Chemical Biology is a gold open access journal dedicated to publishing and disseminating exceptional, breakthrough research and high-quality reviews at the interface of chemistry and biology. We welcome contributions from across the breadth of the chemical biology field. This includes Sensing and Imaging, Bioorthogonal chemistry, Biosynthesis, Biomimetics and Bioengineering, Synthetic biology, Directed evolution, Drugs development and mechanism of action, Glycoscience, Natural products, Nucleic acids, Peptides, Phenotypic screening, Proteins (including protein-protein interactions, modifications, structure and function) We are particularly interested in reports on the application of chemical tools to probe, explore and visualize biological systems and processes to provide insights into molecular mechanisms in health and disease. We also encourage translational research that bridges chemistry and chemical biology to medicine.

RSC Medicinal Chemistry publishes significant research in medicinal chemistry and related drug discovery science. Research articles published in RSC Medicinal Chemistry must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field. Topics within the journal's scope include, but are not limited to: design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities; modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value; novel methodologies and technologies in the broader chemical and biological sciences; computational, machine learning and artificial intelligence (AI) studies are welcome where they significantly advance medicinal chemistry knowledge; studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics; studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence; studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery system of conjugation with novel delivery vectors.

Recent Patents on Anti-Cancer Drug Discovery publishes review/mini review and research articles that reflect or deal with studies in relation to a patent, application of reported patents in a study, discussion of comparison of results regarding application of a given patent, etc., and also guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs, targets & predictive biomarkers & drug efficacy biomarkers. The journal also publishes book reviews of eBooks and books on anti-cancer drug discovery. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-cancer drug discovery.

Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment.Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Portuguese Society of Radiotherapy–Oncology, the Romanian Society of Radiotherapy and Medical Oncology, the Latin American Association for Radiation Oncology and the Grupo Oncólogico Catalan Occitano.Wersja pierwotna czasopisma jest wersja internetowa.

Seminars in Cancer Biology is a review journal dedicated to keeping scientists informed of developments in the field of molecular oncology on a topic by topic basis. Each issue is thematic in approach, devoted to an important topic of interest to cancer biologists, from the underlying genetic and molecular causes of cellular transformation and cancer to the molecular basis of potential therapies. Every issue is edited by a guest editor, an internationally acknowledged expert in the field, and contains six to eight authoritative invited reviews on different aspects of the subject area. The aim of each issue is to provide a coordinated, readable, and lively review of a selected area, published rapidly to ensure currency.Topics covered in earlier issues include:• Tumour suppressor genes• Protein kinases in signal transduction• Steroids and their receptors• Transgenic mice in cancer research• Apoptosis and Cancer• RNA interference in cancer biology and treatment• Oncogenes as therapeutic targetsBenefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.Seminars in Radiation Oncology has an Impact Factor of 4.312 and is ranked 10th of 90 journals in Radiology, Nuclear Medicine & Medical Imaging category and 38th of 141 in Oncology category on the 2009 Journal Citation Reports®, published by Thomson Reuters.2011 Topics: Volume 21, Issues 1-4JanuaryEarly Stage Breast CancerLori Pierce, MDAprilMetabolic and Functional Imaging with Radiation TherapyJames M. Balter, PhDJulyRectal CancerBrian Czito, MD, and Christopher Willett, MDOctoberLiver Tumors (primary and metastatic)Laura Dawson, MD

Despite the major efforts made in oncology over the past ten years, only relatively modest improvements have been made in the conventional treatment of cancer. Recently, a better understanding of molecular pathways has provided pathologists with clues to the parthenogenesis of the disease and multiple targets for new strategies. New treatments, monoclonal antibodies or small molecules, have emerged targeting these pathways and inhibiting tumor growth and progression. These 'mabs' and 'nibs' constitute a new language with its own grammar that oncologists have to learn. Significant work remains in controlling theses processes and understanding these new compounds. This journal aims to be a pragmatic tool for all physicians committed to the field, focusing on insight into the basic science of cellular functions, critical reviews of clinical data. The Société française d'angiogenèse is affiliated to the journal.

Technology in Cancer Research and Treatment (TCRT) welcomes manuscripts from active investigators involved in technologies devoted to early diagnosis, treatment, and palliation of cancer. TCRT will include both experimental and theoretical investigations. Among the topics that will be covered are MRI, including functional MRI, spiral CT, PET, optical spectroscopy, computer-aided reconstruction of tumors, computer-aided drug design, stereotactic radiosurgery, cryosurgery, brachytherapy, electroporation, photodynamic therapy, gene therapy, cancer vaccine, proteomics, and genomics, as they impact cancer research and treatment. Special emphasis will be given to non-invasive techniques. TCRT publishes original articles, express communications, opinion pieces, and timely reviews. No case report or a single institute experience will be considered for publication.

Oncology and hematology professionals are continuously charged with staying on the cutting–edge of new medical treatments and technologies to foster better cancer patient care and practice management. To that end, The Oncologist® is dedicated to translating the latest research developments into best multimodality practice.Established by oncologists for oncologists, the Journal is committed to helping physicians excel in a challenging and ever-changing environment; to ensure their patients’ rights to the highest level of care from screening and prevention to diagnosis, treatment and management of the disease.Designed specifically for the busy practitioner, The Oncologist is devoted to medical and practice issues for surgical, radiation, and medical oncologists. With emphasis on clear, concise interpretation, rather than data, the Journal's articles are meant to impact the practice of oncology and to facilitate significant communication in the introduction and application of new advancements.The Oncologist'sSenior Editors believe that the various oncology subspecialists should share the same information base and read the same journal. It is up to us, as leaders in this field, to defend the patient's needs and rights and to assure that the patient has an advocate. In order to do so, we have to be united and fully informed. We pledge to put the best and latest information on cancer management before our readership, to help prepare them for the future, and to do their best as a team to improve outcomes and quality of life for every patient.Manuscripts are reviewed by two or more field experts and, when accepted, are published expeditiously—generally within 12 weeks. When a contribution is of such relevance as to significantly impact public health, authors may request Fast Track Review for a Rapid Communication, in which case an editorial decision will be made within 2 weeks of submission.The Oncologist challenges its readers to understand what is new and better, to glimpse the future, not only in terms of research, but also in terms of new team approaches to disease management. In short, we want our readers to explore how cancer medicine could be and will be practiced now and throughout the 21st century.CORRESPONDENCEEditorial correspondence, including submissions for publication or letters to the Editor, should be addressed to the Executive Editor. Submissions for publication in the Fundamentals in Cancer Medicine section should also be addressed to the Executive Editor.Information for Authors can be found at the back of each issue, or contact the AlphaMed Press Editorial Office.Advertising: Correspondence and rate requests should be addressed to the Publisher.Change of Address notices: Both the subscriber's old and new address should be e-mailed to AlphaMed Press at least one month in advance. You can also mail the information to: AlphaMed Press, c/o Cambey & West, PO Box 412, Congers, New York 10920-9914 USA.

Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

'Tumor Biology' is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM), an international journal publishing original research, mini-reviews and research commentaries on experimental and clinical cancer research. The Journal places special emphasis on articles covering all aspects of tumor markers and tumor targeting, but studies in other areas of clinical and translational cancer research are considered. The Editors also welcome proposals for 'Mini-Reviews' and 'Research Commentaries'. Manuscript categories include Editorials, Research Articles, Reviews, Research Commentaries, and Workshop Reports.